Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...Treatment...
...Transplant Eligible...
Patients should be referred to a transplant ce...
...ologic age and renal function should not...
...optimal regimen and number of cycles remain unp...
Upfront transplant should be offered t...
...gents associated with stem cell toxicity, such...
...le stem cell collection (sufficient for more than...
...minimal response required to proceed to S...
...halan is the recommended conditioning...
...ous SCT should not be routinely recommended. ( EB...
...ge or delayed SCT may be used as consolidation at...
...transplant for multiple myeloma i...
...therapy is not routinely recommended but may b...
...de maintenance therapy should be routinely off...
...intolerant of or unable to receive lena...
...high-risk patients, maintenance therapy with a...
...ere is insufficient evidence to make modification...
...and depth of response should be ass...
...goal of initial therapy for transplant...
...ommended that depth of response be asses...
Whole-body low dose CT scan has been shown to be s...
...Transplan...
...ial treatment recommendations for patients w...
Initial treatment for patients with mult...
...plet therapies for patients with multiple myeloma...
...sicians/patients should balance the potentia...
...uous therapy should be offered over f...
...of initial therapy for transplant ineligible...
...response for all patients should...
...ere is insufficient evidence to support ch...
...ion of therapy, one should define patient...
...nded that patients be monitored cl...
...Relapsed Di...
...or biochemically relapsed myeloma should be in...
...inically relapsed patients with symptoms due...
...herapy should be administered on first...
...tment of relapsed multiple myeloma ma...
...apies should be taken into consideration when...
...logous stem cell transplantation, if not r...
...s of the patients should be assessed using th...
...peat risk assessment at the time of relapse...
...t of other risk factors such as renal insu...
...patients with genetic high-risk disease...
In patients with renal insufficiency, drugs s...
...patients with plasma cell leukemia or...
...response criteria should be used...
...parameters need to be followed including...
...cluding marrow and imaging should be confi...
...sponse assessment should be performed after on...
...thm On Management of Patients with Multip...
...Drugs Used in the Management of Patients W...
...le 2. Diagnostic Criteria for Active Multiple Myel...
...ed International Staging System (R-ISS...
...4. Comparison of Select Risk Prediction...
...IMWG Response Criteria Response...
...ble 6. Estimated Cost of Drugs for Mul...